๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Control of hormonal treatment of carcinoma of the prostate

โœ Scribed by Frick, J.

Publisher
Springer
Year
1973
Tongue
English
Weight
158 KB
Volume
1
Category
Article
ISSN
0300-5623

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Combined hormonal therapy with high-dose
Combined hormonal therapy with high-dose diethylstilbestrol diphosphate (DES-DP) intravenous infusion plus vindesine (VND) for the treatment of advanced prostatic carcinoma: A controlled study
โœ Juan C. Cervellino; Carlos E. Araujo; Claudia Pirisi; Oscar Podskubka; Eduardo M ๐Ÿ“‚ Article ๐Ÿ“… 1990 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 335 KB

Fifty-one patients with stage D prostate cancer, who had failed primary hormone treatment, were treated with diethylstilbestrol diphosphate (DES-DP) 1.5 g 24 hr intravenous infusion from day 1 to day 7 (group A). In group B, patients were treated with DES-DP as in A, plus vindesine (VND) 3 mg/m2 int

Carcinoma of prostate: Case against imme
Carcinoma of prostate: Case against immediate hormonal therapy
โœ Smith, Philip H. ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 429 KB ๐Ÿ‘ 2 views

The Urologist is anxious to cure patients where possible and to minimize the impact of the disease where treatment is palliative. Within the pelvis atten-

The addition of chemotherapy to hormonal
The addition of chemotherapy to hormonal therapy for treatment of patients with metastatic carcinoma of the prostate
โœ R. P. Gibbons; S. Beckley; M. F. Brady; T. M. Chu; J. B. Dekernion; C. Dhabuwala ๐Ÿ“‚ Article ๐Ÿ“… 1983 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 674 KB

## Abstract Patients with advanced prostate carcinoma that had been stabilized by orchiectomy (ORCH) or hormone therapy for at least 3 months, were randomized to either diethylstilbestrol (DES) alone or DES plus Cytoxan or DES plus Emcyt. A total of 188 patients were randomized between July, 1976 a

Bone fractures associated with luteinizi
Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma
โœ Murphy F. Townsend; W. Holt Sanders; Robert O. Northway; Sam D. Graham Jr. ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 78 KB ๐Ÿ‘ 2 views

## Background: Luteinizing hormone-releasing hormone agonists (lhrh-a) have become an established treatment for certain patients with prostate carcinoma. lhrh-a are known to decrease bone mineral density. the purpose of this study was to determine the risk of bone fracture in men receiving lhrh-a f